Aikido Pharma Inc

F:BP2M

AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its pipeline consists of patented technology from universities and researchers. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is focused on the treatment of three different cancers and multiple types of viral infections. The company is also developing a spectrum of antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Ebolavirus and Marburg virus. Its subsidiaries include Nuta Technology Corp., Spherix Portfolio Acquisition II, Inc., Guidance IP, LLC, Directional IP, LLC, Spherix Management Services, LLC (SMS), Spherix Delaware Merger Sub Inc., Spherix Merger Subsidiary, Inc and NNPT, LLC.